Exhibit 10.1
AMYLIN PHARMACEUTICALS,
INC.
2003 NON-EMPLOYEE
DIRECTORS’ STOCK OPTION PLAN
ADOPTED APRIL 2,
2003
APPROVED BY STOCKHOLDERS
MAY 14, 2003
EFFECTIVE DATE: APRIL 2, 2003
LAST AMENDED: MARCH 16, 2009
1.
PURPOSES AND RELATIONSHIP WITH
THE COMPANY’S 2001 EQUITY INCENTIVE PLAN.
(a)
Eligible Option
Recipients. The
persons eligible for Initial Grants and Annual Grants are the
Non-Employee Directors of the Company.
(b)
Available Options.
The purpose of the Plan is to
provide a means by which Non-Employee Directors may be given an
opportunity to benefit from increases in the value of the Common
Stock through the granting of Nonstatutory Stock
Options.
(c)
General Purpose.
The Company, by means of the
Plan, seeks to retain the services of its Non-Employee Directors,
to secure and retain the services of new Non-Employee Directors and
to provide incentives for such persons to exert maximum efforts for
the success of the Company and its Affiliates.
(d)
Relationship with the
Company’s 2001 Equity Incentive Plan. All Options granted pursuant to the Plan
shall be deemed to have been issued under and pursuant to the terms
of the Incentive Plan and subject to all the terms and conditions
of the Incentive Plan except to the extent otherwise provided for
in the Plan. In the event that any of the terms or conditions
of the Incentive Plan are inconsistent with or in conflict with any
of the terms or conditions of the Plan or the Options, the terms
and conditions of the Plan or the Options shall control.
2.
DEFINITIONS.
(a)
“Affiliate”
means any parent corporation or
subsidiary corporation of the Company, whether now or hereafter
existing, as those terms are defined in Sections 424(e) and
(f), respectively, of the Code.
(b)
“Annual
Grant” means an
Option granted annually to all Non-Employee Directors who meet the
criteria specified in subsection 6(b) of the Plan.
(c)
“Annual
Meeting” means
the annual meeting of the stockholders of the Company.
(d)
“Board” means the Board of Directors of the
Company.
(e)
“Change in
Control” means
the occurrence of any of the following: (i) any
“person,” as such term is used in Sections
13(d) and 14(d) of the Exchange Act (other than the
Company, a subsidiary, an affiliate, or a Company employee benefit
plan, including any trustee
1
of such plan acting as trustee) is or becomes
the “beneficial owner” (as defined in Rule 13d-3
under the Exchange Act), directly or indirectly, of securities of
the Company representing 50% or more of the combined voting power
of the Company’s then outstanding securities other than by
virtue of a merger, consolidation or similar transaction;
(ii) there is consummated a sale or other disposition of all
or substantially all of the assets of the Company (other than a
sale to an entity where at least 50% of the combined voting power
of the voting securities of such entity are owned by the
stockholders of the Company in substantially the same proportions
as their ownership of the Company immediately prior to such sale);
(iii) there is consummated a merger, consolidation or similar
transaction involving (directly or indirectly) the Company and,
immediately after the consummation of such transaction, the
stockholders immediately prior to the consummation of such
transaction do not own, directly or indirectly, outstanding voting
securities representing more than 50% of the combined outstanding
voting power of the surviving entity in such transaction or more
than 50% of the combined outstanding voting power of the parent of
the surviving entity in such transaction.
(f)
“Code” means the Internal Revenue Code of 1986, as
amended.
(g)
“Common
Stock” means
the common stock of the Company.
(h)
“Company”
means Amylin
Pharmaceuticals, Inc., a Delaware corporation.
(i)
“Consultant”
means any person, including an
advisor, whether an individual or an entity, (i) engaged by
the Company or an Affiliate to render consulting or advisory
services and who is compensated for such services or (ii) who
is a member of the Board of Directors of an Affiliate and who is
compensated for such services. However, the term
“Consultant” shall not include Directors who are not
compensated by the Company for their services as Directors, and the
payment of a director’s fee by the Company for services as a
Director shall not cause a Director to be considered a
“Consultant” for purposes of the Plan.
(j)
“Continuous
Service” means
that the Optionholder’s service with the Company or an
Affiliate, whether as an Employee, Director or Consultant, is not
interrupted or terminated. An Optionholder’s Continuous
Service shall not be deemed to have terminated by reason of a
change in the capacity in which such Optionholder renders service
to the Company or an Affiliate as an Employee, Consultant or
Director or a change in the entity for which such Optionholder
renders such service, provided that there is otherwise no
interruption or termination of such Optionholder’s Continuous
Service. For example, a change in status from a Non-Employee
Director of the Company to a Consultant of an Affiliate or an
Employee of the Company will not constitute an interruption of
Continuous Service. The Board or the chief executive officer
of the Company, in that party’s sole discretion, may
determine whether Continuous Service shall be considered
interrupted in the case of any leave of absence approved by that
party, including sick leave, military leave or any other personal
leave.
(k)
“Director”
means a member of the Board of
Directors of the Company.
(l)
“Employee”
means any person employed by the
Company or an Affiliate. A person shall not be deemed an
Employee by reason of such person’s service as a Director
and/or payments of director’s fees to such person.
2
(m)
“Exchange
Act” means the
Securities Exchange Act of 1934, as amended.
(n)
“Fair Market
Value” means,
as of any date, the value of the Common Stock determined as
follows:
(i)
If the Common Stock is listed on any
established stock exchange or traded on any established market, the
Fair Market Value of a share of Common Stock shall be the closing
sales price for such stock as quoted on such exchange or market (or
the exchange or market with the greatest volume of trading in the
Common Stock) on the date of determination, as reported in a source
the Board deems reliable.
(ii)
Unless otherwise provided by the
Board, if there is no closing sales price for the Common Stock on
the date of determination, then the Fair Market Value shall be the
closing selling price on the last preceding date for which such
quotation exists.
(iii)
In the absence of such markets for
the Common Stock, the Fair Market Value shall be determined in good
faith by the Board and in a manner that complies with
Section 409A and 422 of the Code.
(o)
“Incentive
Plan” means the
Company’s 2001 Equity Incentive Plan or any successor equity
incentive plan thereto.
(p)
“Initial
Grant” means an
Option granted to a Non-Employee Director who meets the criteria
specified in subsection 6(a) of the Plan.
(q)
“Non-Employee
Director” means
a Director who is not an Employee.
(r)
“Nonstatutory Stock
Option” means
an Option not intended to qualify as an incentive stock option
within the meaning of Section 422 of the Code and the
regulations promulgated thereunder.
(s)
“Option” means a Nonstatutory Stock Option granted
pursuant to the Plan.
(t)
“Optionholder”
means a person to whom an Option is
granted pursuant to the Plan or, if applicable, such other person
who holds an outstanding Option.
(u)
“Plan” means this Amylin Pharmaceuticals, Inc.
2003 Non-Employee Directors’ Stock Option Plan.
(v)
“Rule 16b-3”
means Rule 16b-3 promulgated
under the Exchange Act or any successor to Rule 16b-3, as in
effect from time to time.
3.
ADMINISTRATION.
(a)
Administration by
Board. The Board
shall administer the Plan.
(b)
Powers of Board.
The Board shall have the
power, subject to, and within the limitations of, the express
provisions of the Plan:
3
(i)
To determine the provisions of each
Option to the extent permitted in the Plan.
(ii)
To construe and interpret the Plan
and Options granted under it, and to establish, amend and revoke
rules and regulations for its administration. The Board,
in the exercise of this power, may correct any defect, omission or
inconsistency in the Plan, in a manner and to the extent it shall
deem necessary or expedient to make the Plan fully
effective.
(iii)
To amend the Plan as provided in
Section 10.
(iv)
Generally, to exercise such powers
and to perform such acts as the Board deems necessary or expedient
to promote the best interests of the Company which are not in
conflict with the provisions of the Plan.
(c)
Effect of Board’s
Decision. All
determinations, interpretations and constructions made by the Board
in good faith shall not be subject to review by any person and
shall be final, binding and conclusive on all persons.
4.
OPTIONS ISSUED UNDER INCENTIVE
PLAN.
All Options granted pursuant to the
Plan shall be deemed to have been issued under the Incentive Plan,
and the shares of Common Stock issuable upon exercise of such
Options shall be issuable out of the shares reserved for issuance
under the Incentive Plan pursuant to Section 4 of the
Incentive Plan.
5.
ELIGIBILITY.
The Options as set forth in
Section 6 automatically shall be granted under the Plan to all
Non-Employee Directors in accordance with the provisions of
Section 6.
6.
NON-DISCRETIONARY
GRANTS.
(a)
Initial Grants.
Each person who is elected or
appointed by the Board or stockholders of the Company for the first
time to be a Non-Employee Director subsequent to April 2, 2003
and who has not served as a Director at any time during the
two-year period immediately preceding the date of such election or
appointment, automatically shall, upon the date of his or
h